A rapid simple point-of-care assay for the detection of SARS-CoV-2 neutralizing antibodies
© The Author(s) 2021..
Background: Neutralizing antibodies (NAbs) prevent pathogens from infecting host cells. Detection of SARS-CoV-2 NAbs is critical to evaluate herd immunity and monitor vaccine efficacy against SARS-CoV-2, the virus that causes COVID-19. All currently available NAb tests are lab-based and time-intensive.
Method: We develop a 10 min cellulose pull-down test to detect NAbs against SARS-CoV-2 from human plasma. The test evaluates the ability of antibodies to disrupt ACE2 receptor-RBD complex formation. The simple, portable, and rapid testing process relies on two key technologies: (i) the vertical-flow paper-based assay format and (ii) the rapid interaction of cellulose binding domain to cellulose paper.
Results: Here we show the construction of a cellulose-based vertical-flow test. The developed test gives above 80% sensitivity and specificity and up to 93% accuracy as compared to two current lab-based methods using COVID-19 convalescent plasma.
Conclusions: A rapid 10 min cellulose based test has been developed for detection of NAb against SARS-CoV-2. The test demonstrates comparable performance to the lab-based tests and can be used at Point-of-Care. Importantly, the approach used for this test can be easily extended to test RBD variants or to evaluate NAbs against other pathogens.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1 |
|---|---|
| Enthalten in: |
Communications medicine - 1(2021) vom: 12., Seite 46 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kongsuphol, Patthara [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 02.11.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1038/s43856-021-00045-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341247812 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341247812 | ||
| 003 | DE-627 | ||
| 005 | 20231226011336.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s43856-021-00045-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1137.xml |
| 035 | |a (DE-627)NLM341247812 | ||
| 035 | |a (NLM)35602218 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kongsuphol, Patthara |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A rapid simple point-of-care assay for the detection of SARS-CoV-2 neutralizing antibodies |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2021. | ||
| 520 | |a Background: Neutralizing antibodies (NAbs) prevent pathogens from infecting host cells. Detection of SARS-CoV-2 NAbs is critical to evaluate herd immunity and monitor vaccine efficacy against SARS-CoV-2, the virus that causes COVID-19. All currently available NAb tests are lab-based and time-intensive | ||
| 520 | |a Method: We develop a 10 min cellulose pull-down test to detect NAbs against SARS-CoV-2 from human plasma. The test evaluates the ability of antibodies to disrupt ACE2 receptor-RBD complex formation. The simple, portable, and rapid testing process relies on two key technologies: (i) the vertical-flow paper-based assay format and (ii) the rapid interaction of cellulose binding domain to cellulose paper | ||
| 520 | |a Results: Here we show the construction of a cellulose-based vertical-flow test. The developed test gives above 80% sensitivity and specificity and up to 93% accuracy as compared to two current lab-based methods using COVID-19 convalescent plasma | ||
| 520 | |a Conclusions: A rapid 10 min cellulose based test has been developed for detection of NAb against SARS-CoV-2. The test demonstrates comparable performance to the lab-based tests and can be used at Point-of-Care. Importantly, the approach used for this test can be easily extended to test RBD variants or to evaluate NAbs against other pathogens | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Diseases | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Jia, Huan |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Hoi Lok |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Shunmuganathan, Bhuvaneshwari D/O |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ming Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Sing Mei |e verfasserin |4 aut | |
| 700 | 1 | |a Ng, Say Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Tambyah, Paul Ananth |e verfasserin |4 aut | |
| 700 | 1 | |a Nasir, Haziq |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Xiaohong |e verfasserin |4 aut | |
| 700 | 1 | |a Tay, Dousabel |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Seunghyeon |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Rashi |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Xinlei |e verfasserin |4 aut | |
| 700 | 1 | |a Kozma, Mary M |e verfasserin |4 aut | |
| 700 | 1 | |a Purushotorman, Kiren |e verfasserin |4 aut | |
| 700 | 1 | |a McBee, Megan E |e verfasserin |4 aut | |
| 700 | 1 | |a MacAry, Paul A |e verfasserin |4 aut | |
| 700 | 1 | |a Sikes, Hadley D |e verfasserin |4 aut | |
| 700 | 1 | |a Preiser, Peter R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Communications medicine |d 2021 |g 1(2021) vom: 12., Seite 46 |w (DE-627)NLM330650033 |x 2730-664X |7 nnns |
| 773 | 1 | 8 | |g volume:1 |g year:2021 |g day:12 |g pages:46 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s43856-021-00045-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1 |j 2021 |b 12 |h 46 | ||